These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 27161705)

  • 41. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process.
    Presta M; Rusnati M; Belleri M; Morbidelli L; Ziche M; Ribatti D
    Cancer Res; 1999 May; 59(10):2417-24. PubMed ID: 10344752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigating the dynamic aspects of drug-protein recognition through a combination of MD and NMR analyses: implications for the development of protein-protein interaction inhibitors.
    Meli M; Pagano K; Ragona L; Colombo G
    PLoS One; 2014; 9(5):e97153. PubMed ID: 24865844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and Discovery of New Collagen V-Derived FGF2-Blocking Natural Peptides Inhibiting Lung Squamous Cell Carcinoma
    Kuang K; Chen X; Wang M; Han W; Qiu X; Jin T; Xu R; Yuan B; Qian M; Li C; Xiang R; Li F; Zhang S; Yang Z; Du J; Li D; Zhang C; Wang Q; Jia T
    J Med Chem; 2024 Jul; ():. PubMed ID: 39045829
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correction to: DNA Damage In situ Ligation followed by Proximity Ligation Assay (DI-PLA).
    Galbiati A; d'Adda di Fagagna F
    Methods Mol Biol; 2019; 1896():C3. PubMed ID: 30997669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correction: Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.
    Petroni G; Bagni G; Iorio J; Duranti C; Lottini T; Stefanini M; Kragol G; Becchetti A; Arcangeli A
    Cell Death Dis; 2020 Mar; 11(3):209. PubMed ID: 32231201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thrombospondin 1 and Its Diverse Roles as a Regulator of Extracellular Matrix in Fibrotic Disease.
    Murphy-Ullrich JE
    J Histochem Cytochem; 2019 Sep; 67(9):683-699. PubMed ID: 31116066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting Difficult Protein-Protein Interactions with Plain and General Computational Approaches.
    Ferraro M; Colombo G
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30181519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From Inflammation to Current and Alternative Therapies Involved in Wound Healing.
    Serra MB; Barroso WA; da Silva NN; Silva SDN; Borges ACR; Abreu IC; Borges MODR
    Int J Inflam; 2017; 2017():3406215. PubMed ID: 28811953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.
    Leali D; Alessi P; Coltrini D; Rusnati M; Zetta L; Presta M
    Curr Pharm Des; 2009; 15(30):3577-89. PubMed ID: 19860702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.
    Pinessi D; Foglieni C; Bugatti A; Moroni E; Resovi A; Ribatti D; Rusnati M; Giavazzi R; Colombo G; Taraboletti G
    Thromb Res; 2016 Apr; 140 Suppl 1():S182. PubMed ID: 27161705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.
    Foglieni C; Pagano K; Lessi M; Bugatti A; Moroni E; Pinessi D; Resovi A; Ribatti D; Bertini S; Ragona L; Bellina F; Rusnati M; Colombo G; Taraboletti G
    Sci Rep; 2016 Mar; 6():23432. PubMed ID: 27000667
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2).
    Rusnati M; Borsotti P; Moroni E; Foglieni C; Chiodelli P; Carminati L; Pinessi D; Annis DS; Paiardi G; Bugatti A; Gori A; Longhi R; Belotti D; Mosher DF; Colombo G; Taraboletti G
    Angiogenesis; 2019 Feb; 22(1):133-144. PubMed ID: 30168023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.
    Pagano K; Torella R; Foglieni C; Bugatti A; Tomaselli S; Zetta L; Presta M; Rusnati M; Taraboletti G; Colombo G; Ragona L
    PLoS One; 2012; 7(5):e36990. PubMed ID: 22606323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.